Aeolus study reports AEOL 10150 successful against acute radiation lung exposure

Aeolus Pharmaceuticals, Inc., announced on Tuesday the results of a U.S. Government funded study concerning the efficacy of the AEOL 10150 drug against acute radiation exposure in the lungs.

The Biomedical Advanced Research and Development Authority funded the study as part of a larger contract to develop AEOL 10150. Aeolus is in the third year of its five year contract with BARDA that could be worth up to $118 million.

In the study, a group of 120 CBA/J mice were exposed to 14.6 Gy of whole thorax lung irradiation. Treatment groups were separated by daily doses of 5mg, 10mg, 25mg or 40mg/kg of AEOL 10150 beginning 24 hours after exposure over the course of 28 days. The details of the study will be published in the near future; the treatment group that received 25 mg/kg showed a survival rate of 40 percent.

"Injection of 25 mg/kg or AEOL10150 24 hours after whole thorax lung irradiation resulted in a four-fold improvement in survival in CBA mice and significant protection of the lungs as measured by differences in wet lung weights and breathing frequency," Aeolus Chief Science Officer Brian Day said. "This study confirms previous studies in animals that demonstrate AEOL 10150's protection of the lungs from both the type of radiation exposure one would experience from a nuclear blast or from radiation therapy for cancer."

The study was the first of eight AEOL 10150 mouse studies, with the results of each study to be reported over the next 12 months.

Organizations in this Story

Aeolus Pharmaceuticals

Want to get notified whenever we write about Aeolus Pharmaceuticals ?
Next time we write about Aeolus Pharmaceuticals, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.